文献速递泌尿男性生殖肿瘤

近20年新发转移性前列腺癌患者生存改善

Improved survival for patients with de novo metastatic prostate cancer in the last 20 years.
PubMed 文献 · Eur J Cancer · 2016-12-23

该研究比较1997年诊断的207例与2007-2013年诊断的316例新发转移性前列腺癌男性患者,均接受初始内分泌治疗。2007-2013年诊断组中位总生存为39.4个月,显著长于1997年诊断组的24.2个月(p<0.0001);前列腺癌特异性死亡的5年累积发生率分别为47%和72%(p<0.0001)。作者认为生存改善可部分归因于领先时间偏倚,也与新型延长生存治疗方案的引入有关。

要点

  • 2007-2013年诊断组中位总生存39.4个月,1997年诊断组为24.2个月(p<0.0001)。
  • 前列腺癌特异性死亡的5年累积发生率:2007-2013年诊断组47%,1997年诊断组72%(p<0.0001)。
  • 1997年诊断组接受手术去势者占57%,2007-2013年诊断组占9%;二线治疗分别有1例和81例(26%)。

核心结论

  • 近20年来新发转移性前列腺癌患者的生存显著改善,改善可部分由领先时间偏倚解释,也与新型延长生存治疗方案的引入有关。

研究设计与样本

  • 研究纳入1997年诊断的207例和2007-2013年诊断的316例新发转移性前列腺癌男性患者,均接受初始内分泌治疗,随访总生存和前列腺癌特异性生存。

主要发现

  • 2007-2013年诊断组中位总生存为39.4个月,1997年诊断组为24.2个月(p<0.0001)。
  • 前列腺癌特异性死亡的5年累积发生率在1997年诊断组为72%,在2007-2013年诊断组为47%(p<0.0001)。
  • 诊断时,2007-2013年诊断组合并症更少、前列腺特异性抗原水平更低、临床肿瘤分期更低。
  • 1997年诊断组接受手术去势的比例为57%,2007-2013年诊断组为9%。
  • 1997年诊断组仅1例接受二线治疗,2007-2013年诊断组有81例(26%)接受二线治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: During recent years, several new life-prolonging therapeutic options have been introduced for patients with metastatic prostate cancer (mPCa). The aim of the present study was to evaluate the changes in the survival of patients diagnosed with mPCa prior to and in the early period of the implementation of these new agents. PATIENTS AND METHODS: The study population consisted of 207 men diagnosed in 1997 and 316 men diagnosed in the period 2007-2013 with de novo mPCa and managed with initial endocrine therapy. Men were followed for overall survival and PCa-specific survival. RESULTS: At the time of diagnosis, men diagnosed in the period 2007-2013 had less co-morbidity, lower prostrate-specific antigen levels and lower clinical tumour categories than men diagnosed in 1997. A significantly higher proportion of men diagnosed in 1997 were managed with surgical castration (57% versus 9%). Only one patient diagnosed in 1997 received second-line therapy compared with 81 men (26%) diagnosed in the period 2007-2013. The median overall survival was significantly longer for men diagnosed between 2007 and 2013 compared with men diagnosed in 1997 (39.4 months versus 24.2 months, p < 0.0001). Likewise, the cumulative incidence of PCa-specific death was higher among men diagnosed in 1997 compared with men diagnosed between 2007 and 2013, with 5-year cumulative incidences of 72% and 47%, respectively (p < 0.0001). CONCLUSION: Survival in men diagnosed with metastatic PCa has improved significantly over time. The improved survival can in part be explained by lead-time bias, but also by the introduction of new life-prolonging treatments.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Berg KD, Thomsen FB, Mikkelsen MK, et al. Improved survival for patients with de novo metastatic prostate cancer in the last 20 years. Eur J Cancer. 2016. PMID: 28024263. doi:10.1016/j.ejca.2016.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。